Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VES-001 by Vesper Bio for Frontotemporal Dementia (FTD): Likelihood of Approval
VES-001 is under clinical development by Vesper Bio and currently in Phase I for Frontotemporal Dementia (FTD). According to GlobalData,...